DK1567653T3 - Recombinant koppevirus, som omfatter i det mindste to kokoppe ATI promoterer - Google Patents

Recombinant koppevirus, som omfatter i det mindste to kokoppe ATI promoterer

Info

Publication number
DK1567653T3
DK1567653T3 DK03789029T DK03789029T DK1567653T3 DK 1567653 T3 DK1567653 T3 DK 1567653T3 DK 03789029 T DK03789029 T DK 03789029T DK 03789029 T DK03789029 T DK 03789029T DK 1567653 T3 DK1567653 T3 DK 1567653T3
Authority
DK
Denmark
Prior art keywords
coconut
seq
ati
smallpox virus
recombinant
Prior art date
Application number
DK03789029T
Other languages
English (en)
Inventor
Sonja Leyrer
Paul Howley
Original Assignee
Bavarian Nordic As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bavarian Nordic As filed Critical Bavarian Nordic As
Application granted granted Critical
Publication of DK1567653T3 publication Critical patent/DK1567653T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/863—Poxviral vectors, e.g. entomopoxvirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK03789029T 2002-11-25 2003-11-12 Recombinant koppevirus, som omfatter i det mindste to kokoppe ATI promoterer DK1567653T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200201814 2002-11-25
PCT/EP2003/012610 WO2004048582A2 (en) 2002-11-25 2003-11-12 Recombinant poxvirus comprising at least two cowpox ati promoters

Publications (1)

Publication Number Publication Date
DK1567653T3 true DK1567653T3 (da) 2007-10-15

Family

ID=32337938

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03789029T DK1567653T3 (da) 2002-11-25 2003-11-12 Recombinant koppevirus, som omfatter i det mindste to kokoppe ATI promoterer

Country Status (21)

Country Link
US (1) US7300658B2 (da)
EP (1) EP1567653B1 (da)
JP (1) JP2006515170A (da)
KR (1) KR20050083839A (da)
CN (1) CN1717488A (da)
AT (1) ATE365220T1 (da)
AU (1) AU2003293675B2 (da)
CA (1) CA2501168A1 (da)
CY (1) CY1106883T1 (da)
DE (1) DE60314541T2 (da)
DK (1) DK1567653T3 (da)
EA (1) EA012723B1 (da)
ES (1) ES2288634T3 (da)
IL (1) IL167844A (da)
MX (1) MXPA05005549A (da)
NO (1) NO20053125D0 (da)
NZ (1) NZ540156A (da)
PL (1) PL375740A1 (da)
PT (1) PT1567653E (da)
UA (1) UA85379C2 (da)
WO (1) WO2004048582A2 (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL212047B1 (pl) * 2000-11-23 2012-08-31 Bavarian Nordic As Zmodyfikowany wirus krowianki szczepu Ankara MVA-BN i jego pochodna, genom i zawierające je kompozycja farmaceutyczna, zwłaszcza szczepionka oraz ich zastosowania
CN102703393A (zh) * 2002-05-16 2012-10-03 巴法里安诺迪克有限公司 表达插入痘病毒基因组中的同源基因的重组痘病毒
US7501127B2 (en) 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
EP2426142A3 (en) * 2006-10-16 2012-06-13 Genelux Corporation Modified vaccinia virus strains for use in a diagnostic and therapeutic method
WO2009152969A1 (en) * 2008-06-20 2009-12-23 Bavarian Nordic A/S Recombinant modified vaccinia virus measles vaccine
CN102325888B (zh) * 2008-11-21 2016-09-07 巴法里安诺迪克有限公司 包含多个同源核苷酸序列的载体
US8394385B2 (en) * 2009-03-13 2013-03-12 Bavarian Nordic A/S Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines
WO2013115884A2 (en) * 2011-11-15 2013-08-08 Trustees Of Boston University Pyridopyrimidinone inhibitors of viruses
US11701418B2 (en) * 2015-01-12 2023-07-18 Geovax, Inc. Replication-deficient modified vaccinia Ankara (MVA) expressing Ebola virus glycoprotein (GP) and matrix protein (VP40)
KR20160140075A (ko) 2015-05-29 2016-12-07 코오롱생명과학 주식회사 폭스바이러스 유래 프로모터 및 이를 포함하는 벡터
FR3042121A1 (fr) 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
EP3380604B1 (en) * 2015-11-24 2022-12-28 GlaxoSmithKline Intellectual Property Development Limited Stable cell lines for retroviral production
JP7110096B2 (ja) * 2015-11-24 2022-08-01 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド レトロウイルス産生のための一時的トランスフェクション法
EP3402802B1 (en) 2016-01-08 2023-04-12 Geovax, Inc. Compositions and methods for generating an immune response to a tumor associated antigen
BR112018015696A2 (pt) 2016-02-03 2018-12-26 Geovax Inc composições e métodos para gerar uma resposta imune para um flavivírus
WO2018031694A1 (en) * 2016-08-09 2018-02-15 City Of Hope Chimeric poxvirus compositions and uses thereof
US11311612B2 (en) 2017-09-19 2022-04-26 Geovax, Inc. Compositions and methods for generating an immune response to treat or prevent malaria
JP2023513611A (ja) 2020-02-14 2023-03-31 ゲオバックス インコーポレイテッド Ｓａｒｓ－ｃｏｖ２に対する免疫応答を誘導するためのワクチン及びその利用
FR3160186A1 (fr) 2024-03-13 2025-09-19 Odimma Therapeutics Vecteur non-viral pour transcription augmentee

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5443964A (en) * 1987-08-10 1995-08-22 Duke University Poxvirus insertion/expression vector
US5759841A (en) * 1990-11-20 1998-06-02 Virogenetics Corporation Immunological composition of measles virus utilizing recombinant poxvirus
UA68327C2 (en) * 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
AU4556597A (en) * 1996-09-24 1998-04-17 Bavarian Nordic Research Institute A/S Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
ATE412762T1 (de) * 1999-05-28 2008-11-15 Helmholtz Zentrum Muenchen Vektor zur integration von heterologen sequenzen in poxvirusgenomen
MXPA03001680A (es) * 2000-08-29 2004-11-01 Wyeth Corp Empaque de particulas de un replicon del virus de acido ribonucleico (arn) de hebra positiva.

Also Published As

Publication number Publication date
EP1567653A2 (en) 2005-08-31
NO20053125L (no) 2005-06-24
KR20050083839A (ko) 2005-08-26
CA2501168A1 (en) 2004-06-10
ATE365220T1 (de) 2007-07-15
CY1106883T1 (el) 2012-09-26
DE60314541T2 (de) 2008-02-28
CN1717488A (zh) 2006-01-04
AU2003293675A1 (en) 2004-06-18
PT1567653E (pt) 2007-10-01
NO20053125D0 (no) 2005-06-24
EA200500879A1 (ru) 2005-10-27
AU2003293675B2 (en) 2009-04-23
WO2004048582A3 (en) 2004-08-12
US20060153874A1 (en) 2006-07-13
WO2004048582A2 (en) 2004-06-10
ES2288634T3 (es) 2008-01-16
PL375740A1 (en) 2005-12-12
UA85379C2 (ru) 2009-01-26
DE60314541D1 (de) 2007-08-02
MXPA05005549A (es) 2005-08-16
EA012723B1 (ru) 2009-12-30
JP2006515170A (ja) 2006-05-25
NZ540156A (en) 2006-11-30
EP1567653B1 (en) 2007-06-20
US7300658B2 (en) 2007-11-27
IL167844A (en) 2011-03-31

Similar Documents

Publication Publication Date Title
CY1106883T1 (el) Ανασυνδυασμενος ιος ευλογιας που περιεχει τουλαχιστον δυο υποκινητες ατι ιου ευλογιας αγελαδας.
EP1335987B2 (en) Modified vaccinia ankara virus variant
RU98101904A (ru) Рекомбинантный вирус mva и его использование
US6869793B2 (en) Recombinant MVA virus expressing dengue virus antigens, and the use thereof in vaccines
MXPA02011545A (es) Virus del sindrome respiratorio y reproductor porcino (peesv), vacuna recombinante para el virus de la viruela.
IL204539A (en) Foxvirus virus containing defective genes and a losing gene
JP2003523721A5 (da)
AU2002337083A1 (en) Vaccinia virus mva-e3l-knockout-mutants and use thereof
JP2004501650A5 (da)
JP2012193198A (ja) ポックスウイルスまたは他の感染性因子に対する免疫の急速な誘導に改変ポックスウイルスを使用する方法
IL164179A0 (en) Expression of genes in modified vaccinia virus ankara by using the cowpox ati promoter
BR0012512A (pt) Genes de calicivìrus felino e vacinas notadamente vacinas recombinadas
ZA202307165B (en) Genomic deletion in african swine fever vaccine allowing efficient growth in stable cell lines
JPWO2021154828A5 (da)
UA84667C2 (ru) Вакцина, направленная против инфекции, вызванной вирусом герпеса болезни марека
CA2430115A1 (en) Recombinant rsv virus expression systems and vaccines
CA2372709A1 (en) Vector for integration of heterologous sequences into poxviral genomes
JP2023528984A (ja) コロナウイルス病に対する組換え修飾ワクシニアウイルスアンカラ（ｍｖａ）ワクチン
AU2002246634A1 (en) Generation of human cytomegalovirus yeast artificial chromosome recombinants
CN101142319B (zh) 基于使用修饰安卡拉痘苗病毒的疫苗
AU2003255315A1 (en) Vaccinia virus host range genes to increase the titer of avipoxviruses
NZ512341A (en) Polynucleotides between 15 and 100 base pairs in length coding for parapoxvirus ovis (PPVO)/vaccinia virus recombinant (VVOV) viral genome fragments
JP2009232836A5 (da)
NZ507942A (en) Viral chimeras comprised of CAEV and HIV-1 genetic elements
CA2562136C (en) Novel infectious bursal disease virus and vaccine containing said virus